We report the use of VP-16 as a single agent for the treatment of nasopharyngeal carcinoma. Our patient, a 16-year-old Black Haitian male, had complete clinical and radiographic response to VP-16. The remission continued for 14 months. The patient experienced minimal toxicity. We believe that the good response, excellent compliance, and minimal toxicity experienced by our patient should encourage more trials of VP-16 as upfront therapy for patients with nasopharygeal carcinoma.
- VP‐16 in NPC
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Cancer Research